WHO Pharmaceuticals Newsletter 2005, No. 01
(2005; 12 pages) Ver el documento en el formato PDF
Índice de contenido
Abrir esta carpeta y ver su contenidoREGULATORY MATTERS
Cerrar esta carpetaSAFETY OF MEDICINES
Ver el documentoATAZANAVIRRITONAVIR - Not to be coadministered with omeprazole
Ver el documentoCELECOXIB - Increased risk of cardiovascular events
Ver el documentoDARBEPOETIN ALFA - Adverse outcomes associated with off-label dosing strategies
Ver el documentoGALANTAMINE - Ineffective and possibly unsafe in mild cognitive impairment
Ver el documentoGLUCOSAMINE - Concerns about hypercholesterolaemic effects
Ver el documentoNAPROXEN - Long-term study indicates cardiovascular risk
Ver el documentoNEVIRAPINE - Not recommended in women with CD4+ cell counts greater than 250 cells/mm3
Ver el documentoPROPOFOL - Adverse events with both low- and high-rate infusions
Ver el documentoROSUVASTATIN - More reports of rhabdomyolysis
Abrir esta carpeta y ver su contenidoDRUGS OF CURRENT INTEREST
Abrir esta carpeta y ver su contenidoFEATURE

CELECOXIB - Increased risk of cardiovascular events

Europe, New Zealand, USA. Pfizer has announced that the US National Cancer Institute Data Safety and Monitoring Board has stopped drug administration in the Adenoma Prevention with Celecoxib (Celebrex; APC) trial, as the risk of major cardiovascular events was significantly higher in patients receiving celecoxib than in patients receiving placebo. The US FDA and the EMEA have issued statements detailing the preliminary results, and have requested the full results for review(1-4).

In the APC study, 2400 patients received celecoxib 400 mg/day, celecoxib 800 mg/day or placebo, for a mean duration of 33 months. The relative risk (RR) of major fatal or nonfatal cardiovascular events (composite endpoint of cardiovascular death, acute myocardial infarction or stroke) was statistically significantly higher in the celecoxib 400 mg/day group (RR 2.5) and in the celecoxib 800 mg/day group (RR 3.4), compared with the placebo group.

Two other celecoxib trials, the Prevention of Spontaneous Adenoma Polyps (PreSAP) trial and the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT), have also been evaluated(4). The PreSAP trial has been stopped, based on the results of the APC trial, although an increased risk of cardiovascular events with celecoxib 400 mg/day compared with placebo was not observed(3). However, the ADAPT study is still ongoing(4).

The FDA has issued an Alert for Practitioners regarding the possible increased risk of cardiovascular events in patients receiving celecoxib(4).

Physicians are encouraged to inform patients of the evolving information about this risk, and are advised to consider alternatives to celecoxib; when this is not appropriate, the lowest effective celecoxib dose should be used. The New Zealand Medicines Adverse Reactions Committee has issued similar advice with regard to all COX-2 inhibitors, broadly supporting the UK National Institute of Clinical Excellence guidance that was distributed to all New Zealand general practitioners(5).


1. FDA Statement, 17 December 2004.Available on the Internet at www.fda.gov

2. EMEA Statement, EMEA/205831/2004, 17 December 2004. Available on the Internet at www.emea.eu.int

3. EMEA Statement, EMEA/212271/2004, 22 December 2004. Available on the Internet at www.emea.eu.int

4. FDA Alert for Practitioners (celecoxib), 17 December 2004. Available on the Internet at www.fda.gov

5. Medsafe Media Release, 21 December 2004. Available on the Internet at www.medsafe.govt.nz

Ir a la sección anterior
Ir a la siguiente sección
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 29 octubre 2018